-
1 Comment
Aequus Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 23.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.3.
Aequus Pharmaceuticals Inc's total revenue rose by 66.9% to $619K since the same quarter in the previous year.
Its net income has increased by 61.9% to $-252K since the same quarter in the previous year.
Finally, its free cash flow grew by 81.1% to $-105K since the same quarter in the previous year.
Based on the above factors, Aequus Pharmaceuticals Inc gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CA0076361033 |
| Sector | Healthcare |
| Beta | 0.64 |
|---|---|
| Market Cap | 7M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 0.0% |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AEQ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
